Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new ...

Pfizer plans to invest $1 billion in China by 2030 to support innovation, diagnostics, and the biotech sector, aligning with ...

Viracta Therapeutics has announced a restructuring to focus on its lead oncology candidate, nana-val, targeting EBV-positive ...

Japanese ophthalmology company Santen Pharmaceutical has crossed the East China Sea in its latest collaboration, announced on ...

GEN1047, GEN3017, and GEN1056—to refocus resources, following its recent $1.8 billion acquisition of ProfoundBio. The move ...

AlloVir will merge with Kalaris Therapeutics in an all-stock transaction, with Kalaris shareholders holding a 75% stake in ...

US generic drugmaker Viatris (Nasdaq: VTRS) announced robust financial results for the third quarter of 2024, driven by ...

Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

According to UNICEF's State of the World's Children 2023 report, in Latin America and the Caribbean, 6.8 million children did ...

Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the ...